IMA

+ Watchlist + Portfolio

ImageneBio, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.58
52-Week Range: $3.94 – $9.10
Market Cap: $52.22M
P/E (TTM): —
EPS (TTM): -4.09
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.37
PEG Ratio: —
Return on Equity: -82.68%
Return on Assets: -43.06%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 21.47
Debt/Equity: 0.01
Total Debt: $1.91M
Free Cash Flow: $-23.21M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-82.02M

IMA Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$7.96M	$3.50M	$800.00K
Research & Development	$21.93M	$32.11M	$28.52M
Selling, General & Admin	$7.96M	$8.39M	$20.73M
Operating Expenses	$29.89M	$40.50M	$49.25M
Operating Income	-$21.93M	-$37.00M	-$48.45M
EBITDA	-$18.83M	-$35.47M	-$47.42M
Pretax Income	-$20.87M	-$36.55M	-$45.70M
Income Tax	$280.00K	$13.00K	-$350.00K
Net Income	-$21.15M	-$36.57M	-$45.35M
Diluted EPS	-2.87	-4.33	-9.64
Diluted Shares	11.18M	11.18M	4.87M

IMA Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	$15.32M	$12.12M	$94.53M
Receivables	$223.00K	$83.00K	$1.30M
Current Assets	$25.90M	$12.47M	$140.29M
Total Assets	$31.25M	$15.92M	$152.98M
Current Liabilities	$9.49M	$17.21M	$11.23M
Total Debt	$983.00K	$8.05M	$2.98M
Total Liabilities	$157.35M	$176.49M	$19.84M
Retained Earnings	-$143.33M	-$179.90M	-$230.05M
Shareholders' Equity	-$126.11M	-$160.56M	$133.14M
Working Capital	$16.41M	-$4.74M	$129.05M

IMA Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.23M	-$21.32M	-$47.84M
Capital Expenditure	-$305.00K	—	—
Free Cash Flow	-$18.54M	-$21.32M	-$47.84M
Depreciation & Amortisation	$3.10M	$1.53M	$1.03M
Stock-Based Compensation	—	$0.00	$15.39M
Investing Cash Flow	-$10.45M	$11.12M	-$5.81M
Financing Cash Flow	$150.00K	$6.91M	$135.47M
Net Change in Cash	-$28.54M	-$3.29M	$81.81M

IMA Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$800.00K	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.76M	$4.04M	$5.65M	$15.56M	$3.27M	$5.96M	$6.67M
Selling, General & Admin	$2.38M	$2.75M	$1.71M	$11.04M	$5.23M	$6.12M	$5.12M
Operating Expenses	$6.14M	$6.79M	$7.36M	$26.59M	$8.50M	$12.08M	$11.78M
Operating Income	-$6.14M	-$6.00M	-$7.36M	-$26.59M	-$8.50M	-$12.08M	-$11.78M
EBITDA	-$6.05M	-$5.92M	-$7.28M	-$26.28M	-$7.94M	-$11.90M	-$11.61M
Pretax Income	-$4.80M	-$6.08M	-$7.58M	-$24.85M	-$7.18M	-$10.61M	-$10.16M
Income Tax	$13.00K	$0.00	$0.00	-$74.00K	-$276.00K	$10.00K	$16.00K
Net Income	-$4.81M	-$6.08M	-$7.58M	-$24.78M	-$6.91M	-$10.62M	-$10.18M
Diluted EPS	—	-0.82	-0.96	-2.91	—	-0.95	-0.63
Diluted Shares	—	11.18M	11.18M	8.53M	—	11.21M	16.16M

IMA Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	—	—	$12.12M	$103.16M	$94.53M	$76.05M	$94.68M
Receivables	—	—	$83.00K	$728.00K	$1.30M	—	—
Current Assets	—	—	$12.47M	$147.53M	$140.29M	$122.01M	$141.11M
Total Assets	—	—	$15.92M	$160.88M	$152.98M	$136.68M	$152.04M
Current Liabilities	—	—	$17.21M	$11.14M	$11.23M	$6.63M	$6.57M
Total Debt	—	—	$8.05M	$3.44M	$2.98M	$2.42M	$1.91M
Total Liabilities	—	—	$176.49M	$21.05M	$19.84M	$13.36M	$9.97M
Retained Earnings	—	—	-$179.90M	-$223.14M	-$230.05M	-$240.67M	-$250.85M
Shareholders' Equity	—	—	-$160.56M	$139.83M	$133.14M	$123.33M	$142.07M
Working Capital	—	—	-$4.74M	$136.39M	$129.05M	$115.37M	$134.54M

IMA Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	—	—	-$11.90M	-$21.50M	-$7.22M	-$14.80M	-$9.07M
Free Cash Flow	—	—	-$11.90M	-$21.50M	-$7.22M	-$14.80M	-$9.07M
Depreciation & Amortisation	—	—	$82.00K	$310.00K	$561.00K	$174.00K	$176.00K
Stock-Based Compensation	—	—	$0.00	$15.28M	$51.00K	$876.00K	$911.00K
Investing Cash Flow	—	—	$0.00	-$4.45M	-$1.36M	-$440.00K	-$346.00K
Financing Cash Flow	—	—	$13.02M	$122.42M	$0.00	-$3.24M	$28.05M
Net Change in Cash	—	—	$1.12M	$96.48M	-$8.58M	-$18.48M	$18.63M

Market Snapshot

About

ImageneBio, Inc. is a biotechnology company focused on developing novel therapeutics for cancer treatment. The company utilizes its proprietary technology platform to identify and develop drug candidates targeting specific cancer pathways. ImageneBio's pipeline includes multiple programs in various stages of preclinical and clinical development. The company aims to address unmet medical needs in oncology through precision medicine approaches.